{"id":46375,"date":"2023-10-04T08:29:35","date_gmt":"2023-10-04T08:29:35","guid":{"rendered":"https:\/\/www.cellink.com\/?p=46375"},"modified":"2023-10-04T08:30:07","modified_gmt":"2023-10-04T08:30:07","slug":"carcinotech-and-cellink-enter-a-partnership","status":"publish","type":"post","link":"https:\/\/www.cellink.com\/carcinotech-and-cellink-enter-a-partnership\/","title":{"rendered":"Carcinotech and CELLINK Enter a Partnership to Develop and Commercialize Protocols for Cancer Models to Provide Improved Speed and Accuracy in the Drug Development Processes"},"content":{"rendered":"<p><strong>Carcinotech and CELLINK plan to revolutionize the drug discovery market by leveraging CELLINK&#8217;s bioprinting solutions and Carcinotech&#8217;s expertise in producing 3D bioprinted living tumors to provide protocols for users to develop cutting-edge cancer models.<\/strong><\/p>\n<p><strong>(<\/strong>October 4<sup>th<\/sup> 2023, Gothenburg, Sweden) Carcinotech and CELLINK are pleased to announce a collaborative partnership to develop and commercialize protocols for the biofabrication of 3D bioprinted tumor models based on cancer cell lines that improve accuracy and rapidly speed up drug development processes, driving down development costs and enabling an improved output. The protocols will be available for use on the BIO CELLX system offered by CELLINK.<\/p>\n<p>Globally, an estimated <a href=\"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.3322\/caac.21660\" target=\"_blank\" rel=\"noopener\">19.3 million <\/a>cancer cases occurred in 2020 alone, with a fatality rate of almost 10.0 million cancer deaths, with breast (11.7%), lung (11.4%), colorectal (10%) and prostate (7.3%) being the most fatal. While cancer continues to affect millions, there are still a limited number of effective therapies available, and those that are available, have a high degree of variation from patient to patient.<\/p>\n<p>Carcinotech has established itself as a leader in producing 3D bioprinted Micro-Tumors as well as 3D models based on cancer cell lines, incorporating CELLINK\u2019s technology for automated workflows that have been perfected over the last 3 years. Working with patient-derived biopsies, immune cells and cancer stem cells to develop 3D bioprinted Micro-Tumors, Carcinotech has been providing the pharmaceutical sector with crucial services in assisting researchers to optimize drug testing workflows. The protocols on the BIO CELLX will leverage cell line based 3D models and will greatly accelerate research timelines. The 3D Cancer Cell Line Models have been developed to include the physiological representative ratio of 5 key cell types relevant to each cancer with widely available cell lines.<\/p>\n<p>\u201cWe are looking forward to seeing the impact of this partnership on the oncology research community and look forward to the advancements that will be made in cancer research through the use of Carcinotech\u2019s optimized cancer models. Combining Carcinotech\u2019s in depth understanding of cancer, and CELLINK\u2019s BIO CELLX system&#8217;s precision and reproducibility, we hope to provide a new degree of efficiency to cancer research workflows,\u201d said Cecilia Edebo, CEO CELLINK<\/p>\n<p>Each of the protocols will enable 3D bioprinted cancer models that have undergone rigorous quality control measures, ensuring their dependability. As part of this agreement between CELLINK and Carcinotech, the protocols will be made available on CELLINK\u2019s BIO CELLX 3D biodispenser. The BIO CELLX is the premier biodispensing system, providing customers with the ability to automate 3D cell culture workflows.\u00a0 By offering these protocols, CELLINK and Carcinotech will enable drug development researchers to rapidly increase speed as well as accuracy of results.<\/p>\n<p>CELLINK and Carcinotech entered their first partnership in 2020 to further advance 3D bioprinting technology for cancer research. This initial collaboration leveraged Carcinotech\u2019s vast expertise in patient derived tumor replicas and CELLINK\u2019s innovative bioinks, Extra Cellular Matrix (ECM) and Laminin based Bioinks, which enable human cells to grow and thrive as they would in the human body.<\/p>\n<p>\u201cWe are excited to continue working with CELLINK, a global leader in 3D bioprinting. Their unique technology as well as high quality bioink, provide revolutionary capabilities to the wider life science and drug discovery market. Their extensive knowledge in 3D bioprinting combined with our expertise in oncology and 3D modelling will help fulfil our shared commitment to accelerate oncology drug development pipelines,\u201d said <a href=\"mailto:ishani.malhotra@carcinotech.co.uk\">Ishani Malhotra,<\/a> CEO and Founder of Carcinotech.<\/p>\n<p><strong>For further information, please contact: <\/strong><\/p>\n<p>Avijit Minocha, Head of Marketing, CELLINK<br \/>\nPhone: +1 617 637 5372<br \/>\nEmail: <a href=\"mailto:akm@cellink.com\">akm@cellink.com<\/a><\/p>\n<p><strong>About CELLINK<\/strong><\/p>\n<p>CELLINK is enabling the future of health as part of BICO, the world\u2019s leading bioconvergence company. When CELLINK\u00a0 released\u00a0 the\u00a0 first\u00a0 universal\u00a0 bioink\u00a0 in\u00a0 2016,\u00a0 it\u00a0 democratized\u00a0 the\u00a0 cost\u00a0 of\u00a0 entry\u00a0 for researchers around the world and played a major role in turning the then up-and-coming field of 3D bioprinting into a thriving $1 billion industry. Today, the company\u2019s best-in-class bioinks, bioprinters, software and services have been cited in over 1000 publications and are trusted by more than 1,600 academic,\u00a0 pharmaceutical\u00a0 and\u00a0 industrial\u00a0 labs. With a comprehensive\u00a0 portfolio\u00a0 of\u00a0 world-class\u00a0 3D bioprinters and bioinks CELLINK\u2019s technology enables the printing of human tissues and organs, which enable faster and more accurate models for drug development, while replacing animal experiments and paving the way to save lives by reducing organ rejection and potentially solve the problem with lack of donors. 2022 CELLINK made a strategic investment to reach our business mission and continue to\u00a0 push\u00a0 the\u00a0 boundaries\u00a0 of\u00a0 how\u00a0 3D\u00a0 bioprinting\u00a0 can\u00a0 contribute\u00a0 to\u00a0 the\u00a0 future\u00a0 of\u00a0 health. Visit www.cellink.com to learn more. BICO is listed on the Nasdaq Stockholm Main Market under BICO.<\/p>\n<p><strong>About Carcinotech<\/strong><\/p>\n<p>Carcinotech is revolutionising cancer research by manufacturing 3D-printed micro-tumours using patient-derived biopsies, primary cells, immune cells, and cancer stem cells. Our advanced offering provides a platform for rapid, ethical, and accurate drug screening, pre-clinical, and personalised medicine testing. Carcinotech\u2019s goal is to accelerate drug screening and enable the delivery of more effective cancer treatments to market. Using patient biopsies, tissue engineering, advanced robotic manufacturing, and quality control to produce highly predictive, assay-ready printed tumours at significant throughput. This provides our clients with a \u201cclinical biopsy\u201d quality model, using isolated patient-specific cells and representing donor-specific cancer heterogeneity. Our vision is to be at the forefront of cancer drug testing and provide personalised medicine testing to each individual suffering from cancer to better their chance of treatment and survival. Working with global partners, leading pharma companies, surgeons, pathologists, and clinicians Carcinotech is changing the face of oncology drug development by working to make this vision a reality.<\/p>\n<p>&nbsp;<\/p>\n\t\t<div data-elementor-type=\"section\" data-elementor-id=\"46383\" class=\"elementor elementor-46383\" data-elementor-post-type=\"elementor_library\">\n\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-6af7825 elementor-section-height-min-height elementor-section-boxed elementor-section-height-default elementor-section-items-middle\" data-id=\"6af7825\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-d605814\" data-id=\"d605814\" data-element_type=\"column\" data-e-type=\"column\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-525ce07 elementor-section-height-min-height elementor-section-boxed elementor-section-height-default\" data-id=\"525ce07\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-a79c994\" data-id=\"a79c994\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-bb7a9d3 elementor-widget elementor-widget-heading\" data-id=\"bb7a9d3\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Partnership Conference 2023<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-782a0b9 elementor-widget elementor-widget-heading\" data-id=\"782a0b9\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h4 class=\"elementor-heading-title elementor-size-large\">October 25 - 27<br><b>United Kingdom<\/b><\/h4>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-52e145b\" data-id=\"52e145b\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-0d21fc3 elementor-widget elementor-widget-text-editor\" data-id=\"0d21fc3\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong>Carcinotech is presenting at this year&#8217;s edition of the CELLINK Partnership conference<\/strong><\/p><p>Join us in listening to inspiring presentations by Carcinotech and other established and upcoming talents within bioprinting. This is an event you won&#8217;t want to miss.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-637828c elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"637828c\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-inner-column elementor-element elementor-element-c211fd5\" data-id=\"c211fd5\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-966d0a6 elementor-align-left elementor-widget__width-auto elementor-widget elementor-widget-button\" data-id=\"966d0a6\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm elementor-animation-shrink\" href=\"https:\/\/www.cellink.com\/partnership-conference\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Information<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-86aaada elementor-align-left elementor-widget__width-auto elementor-widget elementor-widget-button\" data-id=\"86aaada\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm elementor-animation-shrink\" href=\"https:\/\/www.cellink.com\/partnership-conference\/registration\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Registration<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t\n","protected":false},"excerpt":{"rendered":"<p>Carcinotech and CELLINK plan to revolutionize the drug discovery market by leveraging CELLINK&#8217;s bioprinting solutions and Carcinotech&#8217;s expertise in producing 3D bioprinted living tumors to provide protocols for users to develop cutting-edge cancer models. (October 4th 2023, Gothenburg, Sweden) Carcinotech and CELLINK are pleased to announce a collaborative partnership to develop and commercialize protocols for [&hellip;]<\/p>\n","protected":false},"author":202,"featured_media":46377,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[168],"tags":[],"class_list":["post-46375","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-industry-news"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.1 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Carcinotech and CELLINK Enter a Partnership - CELLINK<\/title>\n<meta name=\"description\" content=\"Carcinotech and CELLINK to develop and commercialize protocols for cancer models, aiming to provide improved speed and accuracy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cellink.com\/carcinotech-and-cellink-enter-a-partnership\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Carcinotech and CELLINK Enter a Partnership to Develop and Commercialize Protocols for Cancer Models to Provide Improved Speed and Accuracy in the Drug Development Processes\" \/>\n<meta property=\"og:description\" content=\"Carcinotech and CELLINK to develop and commercialize protocols for cancer models, aiming to provide improved speed and accuracy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cellink.com\/carcinotech-and-cellink-enter-a-partnership\/\" \/>\n<meta property=\"og:site_name\" content=\"CELLINK\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-04T08:29:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-10-04T08:30:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cellink.com\/wp-content\/uploads\/2023\/10\/Carcinotech-CELLINK-Partnership.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1280\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"jesperlindahl\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"jesperlindahl\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.cellink.com\\\/carcinotech-and-cellink-enter-a-partnership\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cellink.com\\\/carcinotech-and-cellink-enter-a-partnership\\\/\"},\"author\":{\"name\":\"jesperlindahl\",\"@id\":\"https:\\\/\\\/www.cellink.com\\\/#\\\/schema\\\/person\\\/887e3030d2f2ce7b0d776dd95a1f86b0\"},\"headline\":\"Carcinotech and CELLINK Enter a Partnership to Develop and Commercialize Protocols for Cancer Models to Provide Improved Speed and Accuracy in the Drug Development Processes\",\"datePublished\":\"2023-10-04T08:29:35+00:00\",\"dateModified\":\"2023-10-04T08:30:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.cellink.com\\\/carcinotech-and-cellink-enter-a-partnership\\\/\"},\"wordCount\":949,\"publisher\":{\"@id\":\"https:\\\/\\\/www.cellink.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cellink.com\\\/carcinotech-and-cellink-enter-a-partnership\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.cellink.com\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/Carcinotech-CELLINK-Partnership.jpg\",\"articleSection\":[\"Industry News\"],\"inLanguage\":\"en-US\",\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/www.cellink.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.cellink.com\\\/carcinotech-and-cellink-enter-a-partnership\\\/\",\"url\":\"https:\\\/\\\/www.cellink.com\\\/carcinotech-and-cellink-enter-a-partnership\\\/\",\"name\":\"Carcinotech and CELLINK Enter a Partnership - CELLINK\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cellink.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.cellink.com\\\/carcinotech-and-cellink-enter-a-partnership\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cellink.com\\\/carcinotech-and-cellink-enter-a-partnership\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.cellink.com\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/Carcinotech-CELLINK-Partnership.jpg\",\"datePublished\":\"2023-10-04T08:29:35+00:00\",\"dateModified\":\"2023-10-04T08:30:07+00:00\",\"description\":\"Carcinotech and CELLINK to develop and commercialize protocols for cancer models, aiming to provide improved speed and accuracy.\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.cellink.com\\\/carcinotech-and-cellink-enter-a-partnership\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.cellink.com\\\/carcinotech-and-cellink-enter-a-partnership\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.cellink.com\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/Carcinotech-CELLINK-Partnership.jpg\",\"contentUrl\":\"https:\\\/\\\/www.cellink.com\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/Carcinotech-CELLINK-Partnership.jpg\",\"width\":1920,\"height\":1280},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.cellink.com\\\/#website\",\"url\":\"https:\\\/\\\/www.cellink.com\\\/\",\"name\":\"CELLINK\",\"description\":\"Creating the Future of Health with 3D Bioprinting, Biodispensing and Cell Culturing\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.cellink.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.cellink.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Organization\",\"Place\"],\"@id\":\"https:\\\/\\\/www.cellink.com\\\/#organization\",\"name\":\"CELLINK\",\"url\":\"https:\\\/\\\/www.cellink.com\\\/\",\"logo\":{\"@id\":\"https:\\\/\\\/www.cellink.com\\\/carcinotech-and-cellink-enter-a-partnership\\\/#local-main-organization-logo\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cellink.com\\\/carcinotech-and-cellink-enter-a-partnership\\\/#local-main-organization-logo\"},\"telephone\":[],\"openingHoursSpecification\":[{\"@type\":\"OpeningHoursSpecification\",\"dayOfWeek\":[\"Monday\",\"Tuesday\",\"Wednesday\",\"Thursday\",\"Friday\",\"Saturday\",\"Sunday\"],\"opens\":\"09:00\",\"closes\":\"17:00\"}]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.cellink.com\\\/#\\\/schema\\\/person\\\/887e3030d2f2ce7b0d776dd95a1f86b0\",\"name\":\"jesperlindahl\"},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.cellink.com\\\/carcinotech-and-cellink-enter-a-partnership\\\/#local-main-organization-logo\",\"url\":\"https:\\\/\\\/www.cellink.com\\\/wp-content\\\/uploads\\\/2021\\\/10\\\/1Logotype_RGB_Cellink_black.png\",\"contentUrl\":\"https:\\\/\\\/www.cellink.com\\\/wp-content\\\/uploads\\\/2021\\\/10\\\/1Logotype_RGB_Cellink_black.png\",\"width\":1200,\"height\":300,\"caption\":\"CELLINK\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Carcinotech and CELLINK Enter a Partnership - CELLINK","description":"Carcinotech and CELLINK to develop and commercialize protocols for cancer models, aiming to provide improved speed and accuracy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cellink.com\/carcinotech-and-cellink-enter-a-partnership\/","og_locale":"en_US","og_type":"article","og_title":"Carcinotech and CELLINK Enter a Partnership to Develop and Commercialize Protocols for Cancer Models to Provide Improved Speed and Accuracy in the Drug Development Processes","og_description":"Carcinotech and CELLINK to develop and commercialize protocols for cancer models, aiming to provide improved speed and accuracy.","og_url":"https:\/\/www.cellink.com\/carcinotech-and-cellink-enter-a-partnership\/","og_site_name":"CELLINK","article_published_time":"2023-10-04T08:29:35+00:00","article_modified_time":"2023-10-04T08:30:07+00:00","og_image":[{"width":1920,"height":1280,"url":"https:\/\/www.cellink.com\/wp-content\/uploads\/2023\/10\/Carcinotech-CELLINK-Partnership.jpg","type":"image\/jpeg"}],"author":"jesperlindahl","twitter_card":"summary_large_image","twitter_misc":{"Written by":"jesperlindahl","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.cellink.com\/carcinotech-and-cellink-enter-a-partnership\/#article","isPartOf":{"@id":"https:\/\/www.cellink.com\/carcinotech-and-cellink-enter-a-partnership\/"},"author":{"name":"jesperlindahl","@id":"https:\/\/www.cellink.com\/#\/schema\/person\/887e3030d2f2ce7b0d776dd95a1f86b0"},"headline":"Carcinotech and CELLINK Enter a Partnership to Develop and Commercialize Protocols for Cancer Models to Provide Improved Speed and Accuracy in the Drug Development Processes","datePublished":"2023-10-04T08:29:35+00:00","dateModified":"2023-10-04T08:30:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.cellink.com\/carcinotech-and-cellink-enter-a-partnership\/"},"wordCount":949,"publisher":{"@id":"https:\/\/www.cellink.com\/#organization"},"image":{"@id":"https:\/\/www.cellink.com\/carcinotech-and-cellink-enter-a-partnership\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cellink.com\/wp-content\/uploads\/2023\/10\/Carcinotech-CELLINK-Partnership.jpg","articleSection":["Industry News"],"inLanguage":"en-US","copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/www.cellink.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/www.cellink.com\/carcinotech-and-cellink-enter-a-partnership\/","url":"https:\/\/www.cellink.com\/carcinotech-and-cellink-enter-a-partnership\/","name":"Carcinotech and CELLINK Enter a Partnership - CELLINK","isPartOf":{"@id":"https:\/\/www.cellink.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cellink.com\/carcinotech-and-cellink-enter-a-partnership\/#primaryimage"},"image":{"@id":"https:\/\/www.cellink.com\/carcinotech-and-cellink-enter-a-partnership\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cellink.com\/wp-content\/uploads\/2023\/10\/Carcinotech-CELLINK-Partnership.jpg","datePublished":"2023-10-04T08:29:35+00:00","dateModified":"2023-10-04T08:30:07+00:00","description":"Carcinotech and CELLINK to develop and commercialize protocols for cancer models, aiming to provide improved speed and accuracy.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cellink.com\/carcinotech-and-cellink-enter-a-partnership\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.cellink.com\/carcinotech-and-cellink-enter-a-partnership\/#primaryimage","url":"https:\/\/www.cellink.com\/wp-content\/uploads\/2023\/10\/Carcinotech-CELLINK-Partnership.jpg","contentUrl":"https:\/\/www.cellink.com\/wp-content\/uploads\/2023\/10\/Carcinotech-CELLINK-Partnership.jpg","width":1920,"height":1280},{"@type":"WebSite","@id":"https:\/\/www.cellink.com\/#website","url":"https:\/\/www.cellink.com\/","name":"CELLINK","description":"Creating the Future of Health with 3D Bioprinting, Biodispensing and Cell Culturing","publisher":{"@id":"https:\/\/www.cellink.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cellink.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Organization","Place"],"@id":"https:\/\/www.cellink.com\/#organization","name":"CELLINK","url":"https:\/\/www.cellink.com\/","logo":{"@id":"https:\/\/www.cellink.com\/carcinotech-and-cellink-enter-a-partnership\/#local-main-organization-logo"},"image":{"@id":"https:\/\/www.cellink.com\/carcinotech-and-cellink-enter-a-partnership\/#local-main-organization-logo"},"telephone":[],"openingHoursSpecification":[{"@type":"OpeningHoursSpecification","dayOfWeek":["Monday","Tuesday","Wednesday","Thursday","Friday","Saturday","Sunday"],"opens":"09:00","closes":"17:00"}]},{"@type":"Person","@id":"https:\/\/www.cellink.com\/#\/schema\/person\/887e3030d2f2ce7b0d776dd95a1f86b0","name":"jesperlindahl"},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.cellink.com\/carcinotech-and-cellink-enter-a-partnership\/#local-main-organization-logo","url":"https:\/\/www.cellink.com\/wp-content\/uploads\/2021\/10\/1Logotype_RGB_Cellink_black.png","contentUrl":"https:\/\/www.cellink.com\/wp-content\/uploads\/2021\/10\/1Logotype_RGB_Cellink_black.png","width":1200,"height":300,"caption":"CELLINK"}]}},"_links":{"self":[{"href":"https:\/\/www.cellink.com\/wp-json\/wp\/v2\/posts\/46375","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cellink.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cellink.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cellink.com\/wp-json\/wp\/v2\/users\/202"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cellink.com\/wp-json\/wp\/v2\/comments?post=46375"}],"version-history":[{"count":8,"href":"https:\/\/www.cellink.com\/wp-json\/wp\/v2\/posts\/46375\/revisions"}],"predecessor-version":[{"id":46387,"href":"https:\/\/www.cellink.com\/wp-json\/wp\/v2\/posts\/46375\/revisions\/46387"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cellink.com\/wp-json\/wp\/v2\/media\/46377"}],"wp:attachment":[{"href":"https:\/\/www.cellink.com\/wp-json\/wp\/v2\/media?parent=46375"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cellink.com\/wp-json\/wp\/v2\/categories?post=46375"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cellink.com\/wp-json\/wp\/v2\/tags?post=46375"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}